Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Summary

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

Timeline

Start

2026-05-11

Primary completion

2030-05-24

Completion

2030-05-24

Drugs

Indications